McGill University Health Centre Launches First Human Trial for HER2-Positive Cancer Radioligand Therapy
Medical Xpress1 min read35 words
The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.
🤖 AI-generated content — This article was automatically summarised from public RSS feeds by AutoBrief. Verify important information with the original source.